Member Info for Scinv_temp

However it does allow us to compare cellular responses to the RBD with avidimab vs the rest (most companies used RBD for their vaccines as well) if scancell have published trial data.

Just found some time to look it up, well done Bermuda. Avidimab was used in fact in the covidity project. I didn't know. But I just looked at the relevant figures and not 100% convinced. With that said, we all know how covidity went, I guess mrna was better than avidimab "enhanced" vaccine :)

You mean enjoy NOT spotting, cause you haven't actually spotted anything🤣

And where is the data?

If you think evidence is a minor detail, that's your opinion. What he meant is a figure they previously published in a patent that on one experiment in a mouse model shows that scib works, including reducing tumour size and activation of t cells and it looks amazing. But on the same patent on another figure and in another mouse model, it shows that iscib 1+ is amazing but scib1 is inactive (0 tumour reduction). The latter figure they also showed in an investor presentation recently. Except since the used a mouse model in which scib1 is clearly inactive, that model is useless in comparing avidimab resulting in better efficacy, since clearly it was not the right model for scib1. That too is dodgy and I have point it out in the past, but that's where the company deducting from the "higher affinity to CD64"

The thing is, one would expect to see the experimental evidence, since so much is riding on this. So where is it?

Why don't you check the first post of this thread then, cause that is exactly what is clearly written, and I didn't write it you know.

Do you even understand what it is telling you?

It CLEARLY says avidimab has nothing to do with increased binding to CD64. It just thinks that *I* am suggesting that, when in fact it is the CEO of scancell who is suggesting it.

Was it your other personality that "blocked" me?

Oh and post the response using as prompt exactly what I wrote, if you dare :)

Like I said, that's on the other end of the antibody. That's what avidimab is for. CD64 however binds to the Fc region, not the variable region of the antibody. Your AI response describes the effect on the binding of the antibody to the corresponding region of its antigen, it is not about binding to CD64 receptor.

What scancell are saying is that it also affects binding on the Fc part (the opposite side) to the CD64 receptor.

It's meant to have increased residence time on the epitope with it's opposite side from where CD64 actually binds. And there is no in vitro data to show that it does that they have made public, as far as I know.

For example, someone with Direct Market Access placing a sell order directly at that price, that is then matched by MMs in the buy quotes. So could it be that the reason all these trades that are shown as sells but are actually all at the buy quote level ARE actually sells because someone bug in the background is offloading?

(Except death or progression or change of treatment, those would be events)

Censored can mean a number of things that all point to one of those 3 things

1. Patient completed follow up per protocol, with no event

2. Patient was censored for the purpose of an interim analysis.

3. Patient is no longer on the trial for whatever reason

I did not say that the company calculated PFS arithmetically. I mentioned it because Bermuda tried to on the other forum.

Bermuda, until they provide the data, there is no way to know. It could be that for the purpose of the interim they censored at the last scan, or some left the trial. Probably a mix.

Scared you, didn't I? What is happening is that for the interim they have to censor patients that have not reached the 97 week timepoint, at their last scan. But it just goes to show that estimating PFS isn't that simply and you need sufficient data to actually draw a conclusion. Also, be careful with AI, no matter how advanced it is. My point about the recist label still stands though.

*pro versions

Come on. We are eager to see what your advanced AI has to say (isn't that what you said? That you use only products versions?)

:)